VKTX - Viking Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $98.67 DETAILS

Stock News

Is Viking Therapeutics a Top Takeover Target?

Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.

May 23, 2026 12:31 PM • fool.com

Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

May 21, 2026 08:36 AM • zacks.com

Could Viking Therapeutics Be the Next Eli Lilly?

Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.

May 21, 2026 04:10 AM • fool.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows: William Blair 46th Annual Growth Stock Conference Details: Viking management will deliver a corporate presentation, followed by a breakout session, and participate in investor meetings.Conference Dates: June 2-4, 2026Presentation Date/Time: Tuesday, June 2nd at 2:00 pm – 2:30 pm CTBreakout session: Tuesday, June 2nd at 2:40 pm – 3:10 pm CTLocation: Chicago, IL Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.

May 21, 2026 03:05 AM • prnewswire.com

Best Weight Loss Drug Stocks to Buy in 2026

Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.

May 20, 2026 07:15 PM • fool.com

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.

May 18, 2026 04:45 PM • fool.com

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.

May 18, 2026 09:55 AM • 247wallst.com

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

May 14, 2026 07:20 AM • zacks.com

Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.

May 14, 2026 05:20 AM • 247wallst.com

Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

May 13, 2026 08:52 AM • zacks.com

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conference SAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity (ECO) in Istanbul, Türkiye. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders.

May 12, 2026 03:05 AM • prnewswire.com

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expected in 2028 and potential $1.3B sales by 2030. A hockey stick inflection could pan out.

May 05, 2026 08:00 AM • seekingalpha.com

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.

May 05, 2026 03:05 AM • prnewswire.com

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months

The Street is bullish on this biotech's prospects, but is the sentiment justified?

May 04, 2026 11:45 AM • fool.com

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.

May 01, 2026 06:45 AM • marketbeat.com

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.

Apr 30, 2026 08:31 AM • zacks.com

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. remains a hold as competitive pressure mounts in the GLP-1 obesity/diabetes space, with its lead VK2735 candidate lagging larger peers. VKTX's Phase 3 VANQUISH studies are fully enrolled, but pivotal data are not expected (by me) until late 2027/early 2028, making near-term catalysts limited. The upcoming Q3 maintenance study readout is a potential wildcard; positive results could enable VKTX to raise additional capital and regain momentum.

Apr 30, 2026 04:53 AM • seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Apr 29, 2026 11:01 PM • seekingalpha.com

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 -- -- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 -- -- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 -- -- Strong Quarter-End Cash Position of $603 Million -- SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.

Apr 29, 2026 12:05 PM • prnewswire.com

Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?

Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.

Apr 28, 2026 07:16 AM • zacks.com